EHA 2017 | Venetoclax and ibrutinib: the future for treating WM
Steven Treon
• 29 Aug 2017
Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, provides us an overview of the future in the treatment of Waldenström’s Macroglobulinemia (WM). Current therapies for WM are not ideal due to their associated side effects, a result of depleting patients of their antibodies and their predisposition to neuropathy, as detailed by Dr. Treon, but the future appears to be promising, especially with the emergence of novel effective drugs such as venetoclax and the optimisation of ibrutinib, and their potential combination for a synergistic clinical benefit. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
